66p 0.0 0.0%
Last Trade - 4:23pm
| Market Cap | ÂŁ180.8m |
| Enterprise Value | ÂŁ173.7m |
| Revenue | ÂŁ5.69m |
| Position in Universe | 854th / 1807 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Sep | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 30.5 | 0.13 | 3.13 | 5.69 | 10.4 | 10.7 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Redx Pharma Plc, is engaged in drug discovery, pre-clinical development and licensing. It is engaged in drug discovery across cancer, infection and autoimmune diseases. It has over three programs like Porcupine RXC004 is a combination with PD-1 / PD-L1 in solid tumor (colorectal cancer), GI-targeted ROCK is focused on Crohn’s disease, Porcupine (REDX06109) is focused on Idiopathic pulmonary fibrosis (IPF), ROCK2 selective is focused on Non-alcoholic Steatohepatitis (NASH) and research in Validated targets (SHP2, AZ collaboration and undisclosed targets) focused in Cancer & Fibrosis which has reached candidate nomination stage. Its anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX004, is a class of antibiotic acting through the type II bacterial topoisomerases.
| Last Annual | September 30th, 2020 |
| Last Interim | September 30th, 2020 |
| Incorporated | September 7, 2010 |
| Public Since | March 27, 2015 |
| No. of Shareholders: | n/a |
| No. of Employees: | 52 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 273,887,213 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Block 33 Mereside Alderley Park, MACCLESFIELD, SK10 4TG, United Kingdom |
| Web | https://www.redxpharma.com/ |
| Phone | +44 151 7064747 |
| Contact | () |
| Auditors | RSM UK Audit LLP |
As of 4:23pm, shares in Redx Pharma are trading at 66p, giving the company a market capitalisation of ÂŁ180.8m. This share price information is delayed by 15 minutes.
Shares in Redx Pharma are currently trading at 66p and the price has moved by 0.700k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Redx Pharma price has moved by 0.676k% over the past year.
Of the analysts with advisory recommendations for Redx Pharma, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Redx Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Redx Pharma is scheduled to issue upcoming financial results on the following dates:
Redx Pharma does not currently pay a dividend.
Redx Pharma does not currently pay a dividend.
Redx Pharma does not currently pay a dividend.
To buy shares in Redx Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Redx Pharma are currently trading at 66p, giving the company a market capitalisation of ÂŁ180.8m.
Here are the trading details for Redx Pharma:
Based on an overall assessment of its quality, value and momentum, Redx Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Redx Pharma are currently priced at 66p. At that level they are trading at 1.52% premium to the analyst consensus target price of 65.01.
Analysts covering Redx Pharma currently have a consensus Earnings Per Share (EPS) forecast of -0.078 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Redx Pharma. Over the past six months, the relative strength of its shares against the market has been 4.28%. At the current price of 66p, shares in Redx Pharma are trading at 33.89% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Redx Pharma.
Redx Pharma's management team is headed by:
Here are the top five shareholders of Redx Pharma based on the size of their shareholding:
